Shire revenue breakdown by business segment: 11.6% from Internal Medicine, 30.2% from Immunology, 18.4% from Neuroscience, 10.0% from Genetic Diseases, 26.2% from Hematology and 3.6% from Other

GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 5.5m | 4.7m | 14.1m | 18.2m | 26.5m | 19.2m | 20.1m | 29.0m | 32.4m | 119.6m | 108.0m | 98.3m | 114.0m | 111.4m | 103.4m | 109.3m | 120.6m | 122.3m | 67.1m | 58.2m | 47.6m | 52.3m |

| (9%) | 16% | (2%) | (7%) | 6% | 10% | 1% | (45%) | 9467% | 70% | 39% | |||||||||||

## Operating expense total | 6.0m | 6.5m | 13.9m | 20.4m | 27.2m | 32.6m | 36.3m | 39.1m | 41.8m | 101.5m | 159.8m | 95.1m | 100.7m | 104.7m | 106.5m | 113.1m | 120.3m | 123.2m | 70.1m | 55.9m | 46.4m | 5.3b |

## Depreciation and amortization | 1.2b | 1.8b | ||||||||||||||||||||

## EBITDA | 32.9m | 40.9m | 34.4m | (1.1m) | (1.5m) | 3.0m | 1.7m | (433.0k) | 3.7m | 1.8m | ||||||||||||

| 33% | 36% | 31% | (1%) | (1%) | 2% | 1% | (1%) | 6% | 4% | ||||||||||||

## EBIT | (526.4k) | (1.9m) | 175.0k | (2.2m) | (735.0k) | (13.3m) | (16.1m) | (10.1m) | (9.4m) | 18.2m | (51.8m) | 3.3m | 13.3m | 6.7m | (3.1m) | (3.9m) | 354.0k | (905.0k) | (3.1m) | 2.3m | 1.1m | 2.5b |

| (10%) | (40%) | 1% | (12%) | (3%) | (69%) | (80%) | (35%) | (29%) | 15% | (48%) | 3% | 12% | 6% | (3%) | (4%) | 0% | (1%) | (5%) | 4% | 2% | 4698% |

## Pre tax profit | (939.6k) | (1.9m) | 1.2m | (762.0k) | (179.0k) | (11.8m) | (14.0m) | (10.7m) | (10.5m) | 22.3m | (54.2m) | 5.1m | 15.8m | 7.1m | (2.9m) | (3.2m) | 1.3m | 626.0k | (5.7m) | 5.6m | 2.4m | 6.3m |

## Income tax expense | (404.0k) | 4.2m | (4.4m) | (16.6m) | (11.3m) | 2.4m | (691.0k) | (2.4m) | 990.0k | 503.0k | 303.0k | 947.0k | 2.9m | (2.6m) | 28.0k | (3.2m) | ||||||

## Net Income | (939.6k) | (1.9m) | 1.2m | (762.0k) | (179.0k) | (12.2m) | (9.8m) | (15.1m) | (10.5m) | 5.7m | (65.5m) | 7.5m | 15.1m | 4.7m | (1.9m) | (2.7m) | 1.6m | 1.6m | (2.9m) | 2.9m | 2.5m | 3.1m |

- Source: SEC Filings

USD | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 1.5b | 1.6b | 1.7b | 1.7b | 2.4b | 3.5b | 3.6b | 3.7b | 3.5b |

## Cost of goods sold | 227.8m | 228.0m | 262.7m | 248.6m | 778.1m | 1.7b | 1.3b | 1.1b | 1.0b |

## Gross profit | 1.3b | 1.3b | 1.4b | 1.5b | 1.7b | 1.7b | 2.2b | 2.6b | 2.5b |

| 85% | 85% | 84% | 85% | 68% | 50% | 63% | 70% | 72% |

## R&D expense | 193.7m | 775.9m | 241.2m | 217.1m | 294.8m | 511.1m | 379.3m | 542.4m | 402.8m |

## General and administrative expense | 506.6m | 627.3m | 575.0m | 609.5m | 675.3m | 875.6m | 888.9m | 899.1m | 859.7m |

## Operating expense total | 700.3m | 1.4b | 816.2m | 826.6m | 970.1m | 1.4b | 1.3b | 1.4b | 1.3b |

## Depreciation and amortization | 213.0m | 354.9m | 364.0m | 434.1m | 482.4m | ||||

## EBIT | 474.6m | 132.6m | 455.8m | 543.9m | 96.2m | (405.9m) | 497.1m | 399.2m | 708.6m |

| 32% | 9% | 28% | 32% | 4% | (12%) | 14% | 11% | 20% |

## Interest expense | 9.6m | 11.3m | 10.7m | 44.7m | 87.2m | 186.9m | 142.3m | 141.3m | 141.8m |

## Interest income | 2.0m | 600.0k | 800.0k | 1.0m | 1.6m | 9.3m | 3.1m | 1.1m | 1.5m |

## Pre tax profit | 471.3m | 119.9m | 455.5m | 491.7m | 16.6m | (597.2m) | 362.4m | 261.5m | 568.1m |

## Income tax expense | (57.4m) | 44.1m | 22.3m | (82.1m) | 70.9m | 229.6m | (6.8m) | (24.3m) | (13.5m) |

## Net Income | 410.4m | 159.6m | 452.8m | 419.0m | (162.1m) | (386.8m) | 375.0m | 240.3m | 550.8m |

- Source: SEC Filings

GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## Cash | 45.7k | 219.3k | 17.0k | 4.0k | 135.5m | 528.8m | 472.4m | |||||||||||||||

## Accounts Receivable | 5.0k | 4.0k | 1.2b | 2.6b | 3.0b | |||||||||||||||||

## Prepaid Expenses | 197.4m | 806.3m | 795.3m | |||||||||||||||||||

## Inventories | 455.3m | 544.8m | 635.4m | 3.6b | 3.3b | |||||||||||||||||

## Current Assets | 6.1m | 7.4m | 22.4m | 16.0m | 21.0m | 41.2m | 21.4m | 5.9m | 7.4m | 72.4m | 51.1m | 75.3m | 116.7m | 143.6m | 148.2m | 145.6m | 148.6m | 156.6m | 151.6m | 158.9m | 7.5b | 175.1m |

## PP&E | 205.5k | 188.0k | 432.0k | 507.0k | 12.1m | 12.3m | 12.7m | 20.7m | 19.5m | 21.3m | 23.3m | 22.9m | 26.9m | 38.8m | 37.4m | 40.7m | 38.7m | 37.0m | 8.4m | 7.0m | 6.5b | 25.0k |

## Goodwill | 225.0k | 166.0k | 4.1b | 17.9b | 19.8b | |||||||||||||||||

## Total Assets | 6.4m | 7.6m | 22.8m | 16.5m | 33.1m | 53.5m | 34.1m | 26.6m | 26.9m | 273.3m | 158.9m | 151.2m | 170.4m | 182.9m | 186.0m | 186.7m | 187.6m | 193.9m | 178.7m | 181.9m | 67.0b | 185.4m |

## Accounts Payable | 398.1k | 533.1k | 486.0k | 1.0m | 2.0m | 594.0k | 673.0k | 88.0k | 1.3m | 1.9m | 730.0k | 356.0k | 2.9m | 295.0k | 4.6m | 2.5m | 3.3m | 1.8m | 424.0k | 486.0k | 4.3b | 238.0k |

## Short-term debt | 1.5b | 3.1b | 2.8b | |||||||||||||||||||

## Current Liabilities | 1.5m | 4.6m | 15.9m | 10.3m | 27.1m | 59.2m | 49.6m | 57.2m | 67.9m | 81.1m | 32.1m | 14.4m | 15.7m | 18.3m | 21.6m | 22.0m | 20.4m | 23.6m | 13.0m | 12.1m | 7.7b | 7.9m |

## Long-term debt | 69.9m | 19.9b | 16.8b | |||||||||||||||||||

## Non-Current Liabilities | 227.5m | 226.7m | 227.2m | 3.6m | 6.6m | 5.5m | 5.5m | 4.3m | 3.4m | 292.0k | 113.0k | 30.3b | 50.0k | |||||||||

## Total Debt | 278.0k | 1.2m | 2.9m | 4.8m | 4.9m | 2.9m | 540.0k | 56.0k | 124.0k | 1.6b | 19.9b | 19.5b | ||||||||||

## Total Liabilities | 1.5m | 4.6m | 15.9m | 10.3m | 27.1m | 59.2m | 49.6m | 57.2m | 67.9m | 308.6m | 258.8m | 241.6m | 19.3m | 24.9m | 27.0m | 27.5m | 24.6m | 26.9m | 13.2m | 12.2m | 38.1b | 8.0m |

## Common Stock | 58.9m | 81.3m | 81.6m | |||||||||||||||||||

## Additional Paid-in Capital | 6.1m | 6.1m | 6.1m | 6.1m | 6.1m | 6.1m | 6.1m | 6.1m | 6.1m | 6.1m | 6.1m | 6.1m | 230.6m | 230.6m | 230.6m | 230.6m | 230.6m | 230.6m | 230.6m | 230.6m | 24.7b | 230.6m |

## Retained Earnings | (939.6k) | (1.9m) | 1.2m | (762.0k) | (179.0k) | (12.2m) | (9.8m) | (15.1m) | (10.5m) | 5.7m | (65.5m) | 7.5m | 15.1m | 4.7m | (1.9m) | (2.7m) | 1.6m | 1.6m | (2.9m) | 2.9m | 5.9b | 3.1m |

## Total Equity | 4.9m | 3.0m | 6.9m | 6.2m | 6.0m | (5.7m) | (15.5m) | (30.5m) | (41.1m) | (35.3m) | (99.9m) | (90.4m) | 151.1m | 157.9m | 159.0m | 159.2m | 163.0m | 167.0m | 165.4m | 169.8m | 28.9b | 177.4m |

## Debt to Equity Ratio | 0.1 x | 0.2 x | 0.5 x | 0.8 x | -0.9 x | -0.2 x | 0 x | 0 x | 0 x | 9.3 x | 0.7 x | 110.1 x | ||||||||||

## Debt to Assets Ratio | 0 x | 0.1 x | 0.2 x | 0.1 x | 0.1 x | 0.1 x | 0 x | 0 x | 0 x | 8.7 x | 0.3 x | 105.4 x | ||||||||||

## Financial Leverage | 1.3 x | 2.5 x | 3.3 x | 2.7 x | 5.5 x | -9.4 x | -2.2 x | -0.9 x | -0.7 x | -7.7 x | -1.6 x | -1.7 x | 1.1 x | 1.2 x | 1.2 x | 1.2 x | 1.2 x | 1.2 x | 1.1 x | 1.1 x | 2.3 x | 1 x |

USD | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 |
---|---|---|---|---|---|---|---|---|---|---|

## Cash | 74.3m | 64.0m | 44.9m | 69.0m | 693.4m | 728.6m | 369.0m | 263.7m | 209.3m | |

## Accounts Receivable | 1.1b | 1.1b | 1.3b | 1.3b | 2.4b | 2.6b | 2.6b | 2.8b | 2.8b | |

## Prepaid Expenses | 216.6m | 221.6m | 215.0m | 314.4m | 733.6m | 665.3m | 787.2m | 778.5m | 779.9m | |

## Inventories | 588.7m | 632.8m | 608.9m | 680.0m | 5.8b | 4.9b | 3.3b | 3.3b | 3.4b | |

## Current Assets | 2.5b | 2.5b | 2.7b | 2.4b | 9.7b | 8.9b | 7.1b | 7.2b | 7.3b | 7.9b |

## PP&E | 821.9m | 816.7m | 795.9m | 837.6m | 6.6b | 6.5b | 6.5b | 6.6b | 6.6b | |

## Goodwill | 4.2b | 4.2b | 4.3b | 6.9b | 13.0b | 14.9b | 19.1b | 19.5b | 19.7b | |

## Total Assets | 17.7b | 17.0b | 17.5b | 24.1b | 70.7b | 69.8b | 66.2b | 67.2b | 67.5b | |

## Accounts Payable | 2.0b | 1.9b | 2.0b | 2.0b | 3.7b | 4.0b | 3.6b | 3.8b | 3.9b | 3.9b |

## Short-term debt | 2.6b | 2.2b | 2.0b | 2.2b | 2.7b | 2.7b | 3.0b | 3.2b | 2.6b | |

## Current Liabilities | 4.9b | 4.3b | 4.3b | 4.3b | 6.9b | 7.1b | 7.0b | 7.4b | 7.5b | |

## Long-term debt | 78.7m | 73.9m | 70.7m | 4.7b | 21.3b | 21.0b | 19.5b | 18.4b | 18.0b | |

## Non-Current Liabilities | 3.8b | 3.6b | 3.6b | 9.4b | 34.1b | 32.9b | 29.4b | 2.8b | 27.4b | |

## Total Debt | 2.6b | 2.3b | 2.1b | 6.9b | 24.0b | 23.7b | 22.5b | 21.6b | 20.6b | |

## Total Liabilities | 8.7b | 7.9b | 7.9b | 13.8b | 41.0b | 40.0b | 36.4b | 35.9b | 34.8b | |

## Common Stock | 58.9m | 58.9m | 58.9m | 59.0m | 81.0m | 81.3m | 81.4m | 81.5m | 81.5m | |

## Additional Paid-in Capital | 4.4b | 4.4b | 4.4b | 4.5b | 24.5b | 24.6b | 24.9b | 25.0b | 25.0b | |

## Retained Earnings | 5.0b | 5.1b | 5.5b | 6.2b | 5.9b | 5.5b | 6.3b | 6.3b | 6.9b | |

## Total Equity | 9.0b | 9.1b | 9.6b | 10.3b | 29.8b | 29.8b | 29.7b | 31.3b | 32.7b | 37.4b |

## Debt to Equity Ratio | 0.3 x | 0.3 x | 0.2 x | 0.7 x | 0.8 x | 0.8 x | 0.8 x | 0.7 x | 0.6 x | |

## Debt to Assets Ratio | 0.1 x | 0.1 x | 0.1 x | 0.3 x | 0.3 x | 0.3 x | 0.3 x | 0.3 x | 0.3 x | |

## Financial Leverage | 2 x | 1.9 x | 1.8 x | 2.3 x | 2.4 x | 2.3 x | 2.2 x | 2.1 x | 2.1 x |

GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## Net Income | (939.6k) | (1.9m) | 1.2m | (762.0k) | (179.0k) | (12.2m) | (9.8m) | (15.1m) | (10.5m) | 5.7m | (65.5m) | 7.5m | 15.1m | 4.7m | (1.9m) | (2.7m) | 1.6m | 1.6m | (2.9m) | 2.9m | 2.5m | 3.1m |

## Depreciation and Amortization | 324.4m | 407.3m | 637.2m | 1.5b | 2.3b | |||||||||||||||||

## Accounts Receivable | (211.4m) | (701.7m) | (487.6m) | |||||||||||||||||||

## Inventories | (63.2m) | (255.8m) | (145.1m) | |||||||||||||||||||

## Accounts Payable | 109.2m | 621.6m | (526.8m) | |||||||||||||||||||

## Cash From Operating Activities | 2.3b | 2.7b | 4.3b | |||||||||||||||||||

## Purchases of PP&E | (157.0m) | (114.7m) | (648.7m) | (798.8m) | ||||||||||||||||||

## Cash From Investing Activities | (360.9m) | (4.0b) | (5.6b) | (18.1b) | (700.9m) | |||||||||||||||||

## Short-term Borrowings | (3.1b) | (16.4b) | (7.7b) | |||||||||||||||||||

## Dividends Paid | (134.4m) | (171.3m) | (281.3m) | |||||||||||||||||||

## Cash From Financing Activities | 439.0m | 15.8b | (3.6b) | |||||||||||||||||||

## Net Change in Cash | (2.8b) | 393.3m | (56.4m) | |||||||||||||||||||

## Interest Paid | (29.9m) | (14.5m) | (20.0m) | (284.0m) | 554.2m | |||||||||||||||||

## Income Taxes Paid | 947.0k | 2.9m | (145.9m) | (431.0m) | 524.7m |

USD | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
---|---|---|---|---|---|---|---|---|---|

## Net Income | 410.4m | 570.0m | 1.0b | 419.0m | 256.9m | (129.9m) | 375.0m | 615.3m | 1.2b |

## Depreciation and Amortization | 120.6m | 291.8m | 457.4m | 168.9m | 429.8m | 877.8m | 486.9m | 1.0b | 1.6b |

## Accounts Receivable | (85.1m) | (84.9m) | (288.1m) | (100.9m) | (181.0m) | (411.2m) | (35.3m) | (181.5m) | (301.5m) |

## Inventories | (22.0m) | (37.4m) | (21.7m) | (32.2m) | (116.4m) | (228.0m) | (151.8m) | (171.6m) | (245.2m) |

## Accounts Payable | 77.5m | (39.8m) | 56.5m | (154.6m) | 342.7m | 315.2m | (671.5m) | (445.1m) | (557.8m) |

## Cash From Operating Activities | 561.6m | 1.0b | 1.6b | 389.5m | 980.4m | 1.5b | 459.1m | 1.7b | 2.7b |

## Purchases of PP&E | (22.3m) | (39.8m) | (62.1m) | (51.6m) | (179.1m) | (402.5m) | (212.5m) | (391.1m) | (565.5m) |

## Cash From Investing Activities | (5.2b) | (5.2b) | (5.6b) | (5.7b) | (17.6b) | (17.8b) | (219.8m) | (355.9m) | (491.2m) |

## Short-term Borrowings | (535.2m) | (1.5b) | (2.5b) | (995.1m) | (1.5b) | (14.6b) | (1.8b) | (3.5b) | (5.7b) |

## Dividends Paid | (110.2m) | (110.2m) | (130.2m) | (130.2m) | (234.7m) | (234.7m) | |||

## Cash From Financing Activities | 1.7b | 1.3b | 1.1b | 5.2b | 17.2b | 16.9b | (401.8m) | (1.6b) | (2.6b) |

## Net Change in Cash | (2.9b) | (2.9b) | (2.9b) | (66.5m) | 557.9m | 593.1m | (159.8m) | (265.1m) | (319.5m) |

## Interest Paid | (5.0m) | (9.9m) | (13.1m) | (13.9m) | (111.4m) | 223.4m | 108.2m | 267.0m | 434.9m |

## Income Taxes Paid | 48.8m | (65.2m) | (97.5m) | (89.6m) | (253.7m) | 355.8m | 23.1m | 176.0m | 308.0m |

Report incorrect company information

FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | |
---|---|---|---|---|

## Phase I Trials Products | 7 | 6 | 6 | 7 |

## Phase II Trials Products | 11 | 6 | 10 | 10 |

## Phase III Trials Products | 7 | 14 | 17 | 15 |

## Phase Approved | 2 | 3 | 4 | 7 |

## Projects in R&D Pipeline | 27 | 29 | 37 | 40 |

## Countries | 68 | 72 | 100 | 100 |

## Preclinical Phase Products | 33 | 33 | 35 | 35 |

## Franchises | 7 | |||

## Manufacturing Sites | 14 | |||

## New Product Launches | 50 | |||

## Products Marketed | 40 |

Report incorrect company information

Shire's employees are reported to be approximately 52% female and 48% male.

Report incorrect company information